By Colin Kellaher

 

Werewolf Therapeutics Inc. on Wednesday said it formed a collaboration and supply agreement with Merck & Co. to study Werewolf's WTX-124 product candidate in combination with Merck's blockbuster cancer drug Keytruda.

Werewolf, a Cambridge, Mass., biopharmaceutical company, said it plans to conduct a Phase 1 clinical trial to evaluate the safety and preliminary efficacy of WTX-124 as a monotherapy and in combination with Keytruda in patients with solid tumors.

Werewolf said it plans to file for U.S. Food and Drug Administration approval of the trial in the first half of 2022.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

August 18, 2021 08:37 ET (12:37 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Merck Charts.